R-P Muller
Overview
Explore the profile of R-P Muller including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
86
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Ott O, Strnad V, Potter R, Hammer J, Hildebrandt G, Resch A, et al.
Strahlenther Onkol
. 2016 May;
180 Suppl 1:109-28.
PMID: 27137924
No abstract available.
2.
Wendt T, Gademann G, Pambor C, von Specht H, Martin T, Baltas D, et al.
Strahlenther Onkol
. 2016 May;
180 Suppl 1:5-87.
PMID: 27137922
No abstract available.
3.
Eich H, Kriz J, Schmidberger H, Boll B, Klimm B, Rancea M, et al.
Strahlenther Onkol
. 2013 Apr;
189(6):445-7.
PMID: 23604187
This report reviews aspects of the German evidence-based guidelines for Hodgkin's lymphoma relevant to radiation oncologists. Stage-adapted treatment is discussed with the focus on radiotherapy. Up-to-date literature citations provide an...
4.
Karstens J, Moll M, Muller R, Bamberg M
Strahlenther Onkol
. 2012 Aug;
188 Suppl 3:326-31.
PMID: 22907576
No abstract available.
5.
Semrau R, Herzog S, Vallbohmer D, Kocher M, Holscher A, Muller R
Strahlenther Onkol
. 2012 Feb;
188(3):226-32.
PMID: 22318327
Background: Radiation oncologists increasingly face elderly cancer patients impaired by comorbidities and reduced performance status. As less data are available for this particular group of patients, the aim of the...
6.
Semrau R, Herzog S, Vallbohmer D, Kocher M, Holscher A, Muller R
Dis Esophagus
. 2011 Dec;
25(6):545-54.
PMID: 22133297
The aim of this study was to assess the efficacy and prognostic factors of definitive radiochemotherapy (RCT) for inoperable esophageal cancer. Between 1995 and 2005 all patients with inoperable esophageal...
7.
Stoelben E, Huber R, Muller R, Wolf J
Internist (Berl)
. 2010 Oct;
51(11):1348-57.
PMID: 20967407
The primary treatment of lung cancer depends on tumor stage. In case of lung cancer in clinical stage I to IIb and T3N1 surgical treatment is recommended. The use of...
8.
[Neoadjuvant therapy of adenocarcinomas of the upper gastrointestinal tract. Status of radiotherapy]
Semrau R, Vallbohmer D, Holscher A, Muller R
Chirurg
. 2009 Oct;
80(11):1035-41.
PMID: 19820906
Radiotherapy in combination with simultaneous chemotherapy can improve survival of advanced esophageal adenocarcinoma. The extent of histopathological tumor regression achieved by the therapy is a relevant prognostic factor for this...
9.
Poortmans P, Collette L, Bartelink H, Struikmans H, Van den Bogaert W, Fourquet A, et al.
Cancer Radiother
. 2008 Sep;
12(6-7):565-70.
PMID: 18760649
Purpose: To investigate the impact of the boost dose to the primary tumour bed in the framework of breast conserving therapy on local control, cosmetic results, fibrosis and overall survival...
10.
Nogova L, Reineke T, Eich H, Josting A, Muller-Hermelink H, Wingbermuhle K, et al.
Ann Oncol
. 2005 Aug;
16(10):1683-7.
PMID: 16093276
Background: Since there are no randomized studies, the treatment of choice for patients with early stage lymphocyte-predominant Hodgkin's lymphoma (LPHL) remains unclear. We thus reviewed all LPHL cases registered in...